Delving into the Latest Updates on Ipsen Pty Ltd. with Synapse

A prospective non-interventional study to evaluate the effect of Triptorelin Embonate (Diphereline (TM) 11.25mg) on lower urinary tract symptoms (LUTS) in Australian prostate cancer patients.

开始日期2011-03-08

申办/合作机构

Ipsen Pty Ltd.

ACTRN12609000226202 / CompletedN/A

An observational, multicentre, open label non interventional programme to assess the long-term safety and efficacy of Somatuline (registered trade mark) Autogel (registered trade mark) in the treatment of neuroendocrine tumours when administered by patients or their partners (Home Injection Group) or administered by healthcare professionals.

开始日期2009-08-05

申办/合作机构

Ipsen Pty Ltd.

ACTRN12608000606381 / CompletedN/A

An observational, multicentre, open label non interventional programme to assess the long-term safety and efficacy of Somatuline (registered trade mark) Autogel (registered trade mark) in the treatment of acromegaly when administered by patients or their partners (Home Injection Group) or administered by healthcare professionals.

开始日期2009-04-14

申办/合作机构

Ipsen Pty Ltd.

100 项与 Ipsen Pty Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Ipsen Pty Ltd. 相关的专利（医药）

登录后查看更多信息

1

项与 Ipsen Pty Ltd. 相关的文献（医药）

Research and Reports in Urology

Effect of triptorelin on lower urinary tract symptoms in Australian prostate cancer patients

Article

作者: Woo, Henry H ; Murphy, Declan G ; Grummet, Jeremy P ; Testa, Gerard M ; Stork, Andrew P ; Chong, Michael

PURPOSEProstate cancer is often comorbidly associated with lower urinary tract symptoms (LUTS), but few studies have assessed the effects of androgen deprivation therapy on LUTS in this patient group.PATIENTS AND METHODSWe conducted a prospective, noninterventional, multicenter, observational study to assess the effectiveness of triptorelin (11.25 mg every 12 weeks) over 48 weeks in men presenting with local stage T3/4 prostate cancer and moderate to severe LUTS (International Prostate Symptom Score [IPSS] >7) in a routine practice setting in Australia.RESULTSOf the 44 men who enrolled, effectiveness data were available for 39 men. By the end of the study, 30% of men no longer met the IPSS criteria for moderate to severe LUTS. The proportion of patients with moderate to severe LUTS was 69.6% (16/23) at week 48 and 76.9% (30/39) at the last available visit (coprimary outcomes). An IPSS reduction of ≥3 from week 0 was observed in 47% of men at week 4, 56% at week 24, 61% (14/23) at week 48, and 61.5% (24/39) at the last available visit. Quality of life was rated as mostly satisfied-to-delighted by 39.5% of patients at week 0, 53.9% at week 24, and 77.3% at week 48. Triptorelin was well tolerated with 8 treatment-related adverse events reported, half of which were hot flushes; 5 patients discontinued due to the reported treatment-related adverse events.CONCLUSIONThis observational study suggests that triptorelin improves moderate to severe LUTS in prostate cancer patients in a routine clinical practice setting.

100 项与 Ipsen Pty Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Ipsen Pty Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

2

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

帕罗伐汀 ( RARγ )	心血管疾病更多	批准上市
苹果酸卡博替尼 ( AXL x RET x ROS1 x TYRO3 x Tie-2 x TrkB x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit x c-Met )	晚期肾细胞癌更多	批准上市